Clik here to view.
Sanofi misses estimates in Q1, announces $1.5B share buyback
Sanofi (NYSE:SNY) shares fell -3% today after the company posted its first-quarter results, missing estimates on Wall Street and revealing plans for a $1.5 billion share buyback program. The Paris,...
View ArticleClik here to view.
Flexion touts interim data from Ph3 trial of osteoarthritis injection
Flexion Therapeutics (NSDQ:FLXN) this week touted updated, interim results from an ongoing Phase IIIb study evaluating the safety and tolerability of repeat administration of its osteoarthritis...
View ArticleClik here to view.
Sales for Tandem Diabetes Care climb 44% in Q1
Shares in Tandem Diabetes Care (NSDQ:TNDM) fell -3% today after the insulin pump maker topped revenue expectations, but missed earnings estimates on Wall Street with its first-quarter results. The San...
View ArticleClik here to view.
United Therapeutics puts $216m on the table to buy rival SteadyMed
United Therapeutics (NSDQ:UTHR) today signed a deal to acquire competitor SteadyMed (NSDQ:STDY) for $4.46 per share in cash at closing and $2.63 per share in cash if the combined company can win...
View ArticleClik here to view.
Aerie launches glaucoma drug in U.S.
Aerie Pharmaceuticals (NSDQ:AERI) today launched its once-daily eye-drop product, Rhopressa, which is designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. The...
View ArticleClik here to view.
Tandem wins CE Mark for t:slim X2 insulin pump
Tandem Diabetes Care (NSDQ:TNDM) said today that its t:slim X2 insulin pump won CE Mark clearance in the European Union. The San Diego, Calif.-based company plans to start selling the device in...
View ArticleClik here to view.
Gilead inks $90m deal with Verily to create “molecular map” of inflammatory...
Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease...
View ArticleClik here to view.
DHS warns on cyber vulnerability with BD’s Pyxis drug-dispensing devices
An array of medication-management systems from Becton Dickinson (NYSE: BDX) are vulnerable to the industry-wide KRACK key-reinstallation cyber attack, according to the company and to the Dept. of...
View ArticleClik here to view.
Regeneron, Sanofi strike pricing deal with Express Scripts for cholesterol drug
Regeneron Pharmaceuticals (NSDQ:REGN) and its partner, Sanofi (NYSE:SNY), have agreed to lower the cost for its cholesterol drug, Praluent, for Express Scripts (NSDQ:ESRX) in exchange for an exclusive...
View ArticleClik here to view.
Drug delivery needs better human factors
Adopting neuroscience-based human factors methods could yield better outcomes for patients, improved communication design and engineering teams, and maybe even help companies build IP. The methods...
View ArticleClik here to view.
Allergan touts 5-year data for Liletta intrauterine contraceptive
Allergan (NYSE:AGN) and its nonprofit partner, Medicines360, touted five-year data today from an on-going pivotal trial of its intrauterine device, Liletta. The levonorgestrel-releasing contraceptive...
View ArticleClik here to view.
NIH launches precision medicine project to collect health data from one...
Credit: NIH The National Institutes of Health will open national enrollment next week for its All of Us research program, aiming to collect health data from at least one million volunteers across the...
View ArticleClik here to view.
J&J’s Janssen acquires cancer-killing virus tech
Johnson & Johnson‘s (NYSE:JNJ) Janssen Biotech said today that it agreed to acquire BeneVir Biopharm and its T-Stealth oncolytic virus platform. The privately-held biopharmaceutical company...
View ArticleClik here to view.
Abbott’s Xience Sierra drug-eluting coronary stent wins reimbursement in Japan
Abbott (NYSE:ABT) said today that it won national reimbursement in Japan for its everolimus-eluting stent, Xience Sierra, which is designed to treat patients with coronary artery disease. The company’s...
View ArticleClik here to view.
Intersect ENT beats The Street with Q1 sales, earnings
Shares in Intersect ENT (NSDQ:XENT) held steady today after the medical device maker topped expectations on Wall Street with its first-quarter results. The Menlo Park, Calif.-based company posted a net...
View ArticleClik here to view.
Insulet inks partnerships to expand into Europe
Insulet (NSDQ:PODD) said today that it inked deals with two partners, Theras Group and Nordic Infucare, to distribute its tubeless insulin pump, Omnipod, in Italy and the Nordic markets starting July...
View ArticleClik here to view.
Dexcom sales climb 30% in Q1, beating estimates on The Street
Dexcom (NSDQ:DXCM) beat expectations on Wall Street yesterday with its first-quarter results, topping analysts’ sales estimates by $12.3 million. The San Diego, Calif.-based company posted a net loss...
View ArticleClik here to view.
Anika swings to a loss in Q1
Shares in Anika Therapeutics (NSDQ:ANIK) fell in premarket activity today after the company missed expectations on Wall Street with its first-quarter results. The Bedford, Mass.-based company swung to...
View ArticleClik here to view.
BD beats The Street with Q2 results
Shares in Becton Dickinson (NYSE: BDX) held steady today after the company beat expectations on Wall Street with its second-quarter results. The Franklin Lakes, N.J.-based company swung to a net loss...
View ArticleClik here to view.
Fresenius fires back at Akorn with counterclaims following failed merger
Fresenius (ETR:FRE) filed counterclaims against generic drugmaker Akorn Inc. (NSDQ:AKRX) this week in Delaware Chancery Court, alleging that Akorn tried to defraud the FDA with falsified testing data....
View Article